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NiOBJECTIVES The aim of this study was to explore the early versus late benefits and risks of dabigatran dual therapy
versus warfarin triple therapy in the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabi-
gatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous
Coronary Intervention) trial.
BACKGROUND Patients with atrial fibrillation who undergo percutaneous coronary intervention are at increased risk
for both bleeding and thrombotic events.
METHODS A total of 2,725 patients with atrial fibrillation underwent percutaneous coronary intervention and were
randomized to receive dabigatran 110 mg, or dabigatran 150 mg plus a P2Y12 inhibitor (and no aspirin), or warfarin plus a
P2Y12 inhibitor plus aspirin. Landmark analysis was performed at 30 and 90 days.
RESULTS There was a consistent and large reduction in major or clinically relevant nonmajor bleeding in patients
randomized to dual therapy during the first 30 days (110 mg: hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.31
to 0.66; p < 0.0001; 150 mg: HR: 0.46; 95% CI: 0.30 to 0.72; p ¼ 0.0006) compared with warfarin triple therapy.
There was early net clinical benefit in both dabigatran groups versus warfarin (110 mg: HR: 0.65; 95% CI: 0.47 to 0.88;
p ¼ 0.0062; 150 mg: HR: 0.54; 95% CI: 0.37 to 0.79; p ¼ 0.0015), due to larger reductions in bleeding than increased
thrombotic events for dabigatran 110 mg and bleeding reduction without increased thrombotic risk for dabigatran 150 mg
dual therapy versus warfarin triple therapy. After the removal of aspirin in the warfarin group, bleeding remained lower
with dabigatran 110 mg and was similar with dabigatran 150 mg versus warfarin.
CONCLUSIONS In RE-DUAL PCI, in which patients in the dual-therapy arms were treated with aspirin for an
average of only 1.6 days, there was early net clinical benefit with both doses of dabigatran dual therapy, without an
increase in thrombotic events with dabigatran 150 mg. This could be helpful in the subset of patients with elevated
risk for both bleeding and thrombotic events. (J Am Coll Cardiol Intv 2021;14:768–80) © 2021 The Authors. Published
by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2021.02.022
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AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
CI = confidence interval
CRNM = clinically relevant
nonmajor
DES = drug-eluting stent(s)
DOAC = direct oral
anticoagulant
DTE = death or
thromboembolic event
HR = hazard ratio
ISTH = International Society on
Thrombosis and Hemostasis
PCI = percutaneous coronary
intervention
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769A trial fibrillation is a disease of increasingimportance in the aging population, affectingapproximately 33 million patients worldwide
(1). An increasing number of patients with atrial fibril-
lation who undergo percutaneous coronary interven-
tion (PCI) require antiplatelet therapy in addition to
systemic anticoagulation, which for many years con-
sisted of warfarin plus low-dose aspirin plus a P2Y12
inhibitor (2–9). In recent years, however, randomized
clinical trials have shown improved bleeding and
similar efficacy with different antithrombotic strate-
gies (10–14). Subsequently, it was suggested that
triple-antithrombotic therapy may be unnecessary
and even harmful for many patients in an era of
newer generation stents and direct oral anticoagu-
lants (DOACs) (15–20).
A recent meta-analysis, which included WOEST
(What Is the Optimal Antiplatelet & Anticoagulant
Therapy in Patients With Oral Anticoagulation and
Coronary Stenting), RE-DUAL PCI (Randomized
Evaluation of Dual Antithrombotic Therapy With
Dabigatran Versus Triple Therapy With Warfarin in
Patients With Nonvalvular Atrial Fibrillation Under-
going Percutaneous Coronary Intervention), PIONEER
AF (A Study Exploring Two Strategies of Rivaroxaban
[JNJ39039039; BAY-59-7939] and One of Oral Vitamin
K Antagonist in Patients With Atrial Fibrillation Who
Undergo Percutaneous Coronary Intervention), and
AUGUSTUS (A Study of Apixaban in Patients With
Atrial Fibrillation, Not Caused by a Heart Valve
Problem, Who Are at Risk for Thrombosis [Blood
Clots] Due to Having Had a Recent Coronary Event,
Such as a Heart Attack or a Procedure to Open the
Vessels of the Heart), showed that patients who
received a DOAC plus a P2Y12 inhibitor after PCI had
less bleeding than those who received a vitamin K
antagonist agent plus dual-antiplatelet therapy (21).
However, it has also recently been suggested that a
higher risk for stent thrombosis may exist when
withdrawing aspirin, especially in the first month
after PCI (22).
The RE-DUAL PCI trial compared 110- and 150-mg
doses of dabigatran plus clopidogrel or ticagrelor
versus triple therapy (23). It was found that patients
receiving dabigatran dual therapy versus warfarin
triple therapy had a significantly reduced bleeding
risk; dabigatran dual therapy was noninferior to
warfarin triple therapy with respect to death orThe authors attest they are in compliance with human studies committe
institutions and Food and Drug Administration guidelines, including patien
visit the Author Center.
Manuscript received September 21, 2020; revised manuscript received Februthromboembolic event (DTE) or unplanned
revascularization (24). We have conducted a
landmark analysis of the RE-DUAL PCI trial
to understand whether dabigatran, aspirin
cessation, or both contributed to the lower
bleeding rates in the dual-therapy arms
versus warfarin. We also focused on the
early time period when aspirin was with-
drawn in the 2 dabigatran groups to explore
thrombotic events between the 2 different
dosing strategies of dabigatran dual
therapy.METHODS
STUDY POPULATION AND TRIAL DESIGN. This
analysis included patients enrolled in the RE-DUAL
PCI trial, an open-label multicenter, randomized
clinical trial, which enrolled patients with non-
valvular atrial fibrillation who had undergone PCI.
Detailed methods and outcomes of this trial have
been published previously (23,24). At the time of
randomization, all patients in the United States and
younger patients in other countries (<80 years of
age; <70 years of age in Japan) were assigned to
receive warfarin triple therapy (warfarin plus clopi-
dogrel or ticagrelor plus aspirin), dual-antithrombotic
therapy with dabigatran 110 mg twice daily plus clo-
pidogrel or ticagrelor, or dual-antithrombotic therapy
with dabigatran 150 mg twice daily plus clopidogrel or
ticagrelor in a 1:1:1 ratio. Older patients outside the
United States ($80 years of age; $70 years of age in
Japan) were randomized to either warfarin triple
therapy or dabigatran 110 mg twice daily plus clopi-
dogrel or ticagrelor in a 1:1 ratio. In the triple-therapy
group, aspirin was discontinued after 90 days in pa-
tients with drug-eluting stents (DES) and 30 days in
patients with bare-metal stents (BMS). Subsequently,
all patients were treated with dual-antithrombotic
therapy with a P2Y12 inhibitor plus warfarin or their
respective doses of dabigatran for 12 months. Because
of the differential timing of aspirin cessation among
BMS patients, they were not included in the explor-
atory landmark analysis at 90 days (but are included
in the Supplemental Appendix). However, they were
included in the primary 30-day landmark analysis and
the net clinical benefit analysis. Institutional Reviewes and animal welfare regulations of the authors’
t consent where appropriate. For more information,
ary 11, 2021, accepted February 11, 2021.
TABLE 1 Analysis of Time to First Adjudicated ISTH MBE or CRNMBE, DTE or Unplanned Revascularization, or NCB Event: ISTH MBE/CRNMBE or DTE or
Unplanned Revascularization
Dabigatran
110 mg DAT Warfarin Triple* HR (95% CI) p Value
Dabigatran
150 mg DAT Warfarin Triple† HR (95% CI) p Value
Before 30 days
Total patients 981 981 763 764
ISTH MBEs/CRNMBEs 40 (4.1) 86 (8.8) 0.45 (0.31–0.66) <0.0001 29 (3.8) 61 (8.0) 0.46 (0.30–0.72) 0.0006
DTE or unplanned
revascularization
28 (2.9) 20 (2.0) 1.39 (0.79–2.47) 0.26 12 (1.6) 17 (2.2) 0.70 (0.33–1.46) 0.34
NCB 66 (6.7) 100 (10.2) 0.65 (0.47–0.88) 0.0062 41 (5.4) 74 (9.7) 0.54 (0.37–0.79) 0.0015
After 30 days
Total patients 912 867 721 679
ISTH MBEs/CRNMBEs 111 (11.9) 178 (20.3) 0.55 (0.43–0.69) <0.0001 125 (17.1) 135 (19.6) 0.82 (0.65–1.05) 0.12
DTE or unplanned
revascularization
121 (12.7) 111 (11.7) 1.09 (0.84–1.40) 0.53 78 (10.4) 81 (11.0) 0.94 (0.69–1.28) 0.67
NCB 196 (21.5) 249 (28.7) 0.70 (0.58–0.85) 0.0002 181 (25.1) 185 (27.2) 0.88 (0.72–1.08) 0.22
Values are n (%). All patients treated with bare-metal stents or drug-eluting stents, randomized to receive warfarin triple therapy for 30 or 90 days and then warfarin plus a P2Y12 inhibitor without aspirin
versus dabigatran 110 mg or 150 mg plus a P2Y12 inhibitor. For the dabigatran 110 mg versus warfarin comparison, the model was stratified by age, nonelderly versus elderly (<70 or $70 years in Japan
and <80 or $80 years elsewhere). For the dabigatran 150 mg versus warfarin comparison, an unstratified model was used, as with other analyses. *All patients who received warfarin triple therapy. †All
patients who received warfarin triple therapy and who qualified for 150-mg dabigatran dual therapy.
CI ¼ confidence interval; CRNMBE ¼ clinically relevant nonmajor bleeding event; DAT ¼ dual-antithrombotic therapy; DTE ¼ death or thromboembolic event; HR ¼ hazard ratio; ISTH ¼ International
Society on Thrombosis and Hemostasis; MBE ¼ major bleeding event(s); NCB ¼ net clinical benefit.
Peterson et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 4 , N O . 7 , 2 0 2 1
Landmark Analysis of RE-DUAL PCI A P R I L 1 2 , 2 0 2 1 : 7 6 8 – 8 0
770Board approval was obtained at all sites, and all pa-
tients provided written informed consent.
ENDPOINTS AND FOLLOW-UP. The primary
endpoint was time to the first major or clinically
relevant nonmajor (CRNM) bleeding event, as defined
by the International Society on Thrombosis and He-
mostasis (ISTH). The main efficacy endpoint was a
composite of time to DTE (myocardial infarction,
stroke, or systemic embolism) or unplanned revas-
cularization. Other secondary endpoints were time to
DTE, stent thrombosis, or myocardial infarction. All
clinical endpoints were centrally adjudicated by in-
dependent committee members who were blinded to
treatment assignment.
STATISTICAL ANALYSIS. Overall, there were 2,725
patients in the RE-DUAL PCI study, 2,251 of whom
(82.6%) had undergone stenting with DES. Time-to-
event analyses were performed using Cox propor-
tional hazards regression models. For comparisons
involving 110-mg dabigatran dual therapy versus
warfarin triple therapy, the models were stratified by
age (older [$70 years in Japan and $80 years else-
where], non-older [<70 years in Japan and <80 years
elsewhere]), as had been done in the primary trial.
Comparisons involving 150-mg dabigatran dual ther-
apy versus warfarin triple therapy are not stratified
for age, because older patients outside the United
States were excluded. As in the original trial, com-
parisons with the 150-mg dabigatran dual-therapy
group were made with patients who received
warfarin triple therapy who were also eligible to
receive 150-mg dabigatran dual therapy. Withgrowing interest in events in the first 30 days, we
performed a landmark analysis at 30 days for all pa-
tients (DES and BMS) (22). For this we also performed
a net clinical benefit analysis; the net clinical benefit
endpoint was time to first ISTH major bleeding or
CRNM bleeding or DTE or unplanned revasculariza-
tion event among all patients who received DES or
BMS (25) (see the Supplemental Appendix for a
schema of methods). Baseline characteristics and
event rates are summarized as number (percentage).
Event rates were compared using Cox proportional
hazards regression models, with corresponding Wald
confidence limits for the hazard ratio (HR).
Landmark analysis was secondarily conducted on
the basis of the pre-specified timing for cessation of
aspirin in the warfarin triple-therapy groups at
90 days for DES and 30 days for BMS (see
Supplemental Figure 1) (26–32). Surviving patients
who were free from the primary bleeding endpoint at
the landmark cutoffs were included for landmark
analysis of the primary endpoint. Surviving patients
were also included for landmark analysis of the pri-
mary and secondary efficacy endpoints, as well as net
clinical benefit, if they were free from the respective
event at the landmark cutoffs. Composite and indi-
vidual endpoints were compared using the afore-
mentioned landmarks.
Recurrent events analysis was conducted using the
Prentice, Williams, and Peterson gap time model.
Piecewise constant regression models were also used
in a time-dependent fashion, dividing the time period
into 2 intervals before and after cutoff and consid-
ering that hazards are proportional within time
CENTRAL ILLUSTRATION 30-Day Landmark: Absolute Risk Difference (%) in Patients Treated With Dabigatran
Dual Therapy and Warfarin Triple Therapy
–10
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Peterson, B.E. et al. J Am Coll Cardiol Intv. 2021;14(7):768–80.
Absolute risk difference during the first 30 days among patients who received dabigatran 110 mg plus a P2Y12 inhibitor versus warfarin triple therapy and dabigatran
150 mg plus a P2Y12 inhibitor versus warfarin triple therapy. Net clinical benefit was a composite of International Society on Thrombosis and Hemostasis (ISTH) major
bleeding or clinically relevant nonmajor bleeding and death or thromboembolic event and unplanned revascularization. CRNM ¼ clinically relevant nonmajor bleeding;
DTE ¼ death or thrombotic event; MB ¼ major bleeding; Revasc ¼ revascularization.
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771intervals but not between them. All p values should
be regarded as exploratory. Statistical analysis was
conducted using SAS version 9.4 (SAS Institute, Cary,
North Carolina).
RESULTS
STUDY POPULATION AND FOLLOW-UP. There were
2,725 patients enrolled in RE-DUAL PCI, all of whom
were included in the main 30-day landmark analysis;
2,251 (82.6%) received a DES and were included in the
secondary 90-day analysis. A total of 1,425 patients
received dabigatran dual therapy (804 received
dabigatran 110 mg and 621 received dabigatran
150 mg), and 826 received warfarin triple therapy. At
the beginning of the landmark period, 1,966 patients
(84.0%) had not yet experienced ISTH major bleeding
or CRNM bleeding (Supplemental Tables 1 and 2,
Supplemental Figure 1). For the 2,251 patients who
received DES, the mean time from PCI to randomi-
zation was 1.5  1.17 days (median 1 day) and medianfollow-up duration was 12.9 months (interquartile
range: 9 to 18 months). A separate analysis was per-
formed on the 404 patients who received BMS.
LANDMARK ANALYSIS AT 30 DAYS AND NET CLINICAL
BENEFIT. There were considerable reductions in the
primary bleeding endpoint in both doses of dabiga-
tran versus warfarin (110 mg: HR: 0.45; 95% confi-
dence interval [CI]: 0.31 to 0.66; p < 0.0001; 150 mg:
HR: 0.46; 95% CI: 0.30 to 0.72; p ¼ 0.0006). Both
doses of dabigatran also had significantly lower rates
of recurrent bleeding events, applying the Prentice,
Williams, and Peterson gap time model for the whole
study period (110 mg: HR: 0.61; 95% CI: 0.51 to 0.72;
p < 0.0001; 150 mg: HR: 0.77; 95% CI: 0.64 to 0.93;
p ¼ 0.0056). In the dabigatran 110 mg group, the
number of DTE or unplanned revascularization
events was numerically higher in the first 30 days (28
[2.9%] vs. (20 [2.0%]; HR: 1.39; 95% CI: 0.79 to 2.47;
p ¼ 0.26), whereas in the dabigatran 150 mg group, no
difference in early risk for thrombotic events











(n ¼ 764) HR (95% CI) p Value




28 (2.9) 20 (2.0) 1.39 (0.79–2.47) 0.26 12 (1.6) 17 (2.2) 0.70 (0.33–1.46) 0.34
DTE events 23 (2.3) 16 (1.6) 1.43 (0.75–2.70) 0.27 10 (1.3) 13 (1.7) 0.76 (0.33–1.73) 0.51
Myocardial infarction 13 (1.3) 7 (0.7) 1.84 (0.73–4.62) 0.19 7 (0.9) 6 (0.8) 1.15 (0.39–3.43) 0.80





121 (12.7) 111 (11.7) 1.09 (0.84–1.40) 0.53 78 (10.4) 81 (11.0) 0.94 (0.69–1.28) 0.67
DTE events 85 (8.9) 67 (7.1) 1.27 (0.92–1.75) 0.14 50 (6.6) 47 (6.4) 1.03 (0.69–1.53) 0.89
Myocardial infarction 31 (3.2) 22 (2.3) 1.40 (0.81–2.42) 0.23 19 (2.5) 16 (2.2) 1.16 (0.60–2.25) 0.66
Stent thrombosis 7 (0.7) 5 (0.5) 1.40 (0.44–4.40) 0.57 1 (0.1) 4 (0.5) ‡
Values are n (%). The main efficacy endpoint is a combination of DTE events (myocardial infarction, stroke, or systemic embolism) or unplanned revascularization. *All patients
who received warfarin triple therapy. †All patients who received warfarin triple therapy and who qualified for 150-mg dabigatran dual therapy. ‡Fewer than 5 events per
treatment comparison or not estimable.
Abbreviations as in Table 1.
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772compared with warfarin could be detected (12 [1.6%]
vs. 17 [2.2%]; HR: 0.70; 95% CI: 0.33 to 1.46;
p ¼ 0.34) (Table 1).
There was early net clinical benefit with both doses
of dabigatran dual therapy versus warfarin triply
therapy (dabigatran 110 mg vs. warfarin: HR: 0.65;
95% CI: 0.47 to 0.88; p ¼ 0.0062; dabigatran 150 mg
vs. warfarin: HR: 0.54; 95% CI: 0.37 to 0.79;
p ¼ 0.0015). With dabigatran 110 mg versus warfarin,
this was due to larger reductions in bleeding than any
increase in thrombotic events. With dabigatran
150 mg versus warfarin, this was due to bleeding
reduction without a numeric increase in thrombotic
risk (Central Illustration, Table 2). In the Kaplan-Meier
analysis of net clinical benefit, visual curve separa-
tion between dabigatran 150 mg and warfarin
occurred early, at approximately day 5. Although
there was also net clinical benefit with dabigatran
110 mg versus warfarin, visual curve separation
occurred later, at about 12 days (Figure 1).
After 30 days, patients treated with dabigatran
110 mg dual therapy versus warfarin triple therapy
continued to have greater net clinical benefit (HR:
0.70; 95% CI: 0.58 to 0.85; p ¼ 0.0002), whereas pa-
tients treated with dabigatran 150 mg versus warfarin
had similar net clinical benefit (HR: 0.88; 95% CI: 0.72
to 1.08; p ¼ 0.22). There was a lower risk for bleeding
among patients treated with 110-mg dabigatran dual
therapy versus warfarin dual therapy and similar risk
for bleeding among patients treated with 150 mgversus warfarin. DTE or unplanned revascularization
was similar among all groups after 30 days (Table 1,
Central Illustration). As expected, HRs from piecewise
constant Cox regression models were very similar to
those seen in the landmark analyses (Supplemental
Table 3).
LANDMARK ANALYSIS AT 90 DAYS AMONG PATIENTS
WHO RECEIVED DES. During the first 90 days, there
was a reduction in the primary endpoint of ISTH
major bleeding or CRNM bleeding in patients who
received DES and dabigatran 110 mg dual therapy
compared with warfarin triple therapy (6.8% vs.
16.3%; HR: 0.40; 95% CI: 0.29 to 0.54; p < 0.0001) and
also in patients who received dabigatran 150 mg dual
therapy compared with warfarin triple therapy (9.0%
vs. 15.7%; HR: 0.54; 95% CI: 0.39 to 0.75; p ¼ 0.0003)
(Figure 2). In the Kaplan-Meier analysis, the curves for
ISTH major bleeding or CRNM bleeding begin to
separate on approximately day 5 after randomiza-
tion (Figure 3).
There were similar rates of the secondary efficacy
endpoints prior to 90 days in patients treated with
dabigatran 110 mg versus warfarin (DTE or unplanned
revascularization: 37 [4.6%] vs. 30 [3.6%]; HR: 1.26;
95% CI: 0.78 to 2.04; p ¼ 0.34; stent thrombosis: 7
[0.9%] vs. 4 [0.5%]; HR: 1.78; 95% CI: 0.52 to 6.08;
p ¼ 0.36) and in patients treated with dabigatran
150 mg versus warfarin (DTE or unplanned revascu-
larization: 24 [3.9%] vs. 25 [3.9%]; HR: 0.97; 95% CI:
FIGURE 1 Landmark Analysis of Net Clinical Benefit Endpoint
All patients treated with drug-eluting stents or bare-metal stents. (A) Events before and after the first 30 days after randomization in patients who received 110
dabigatran dual therapy versus warfarin triple therapy. (B) Events before and after the first 30 days after randomization in patients who received 150 dabigatran dual
therapy versus warfarin triple therapy. DAT ¼ dual-antithrombotic therapy; DE ¼ dabigatran; TAT ¼ triple-antithrombotic therapy.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 4 , N O . 7 , 2 0 2 1 Peterson et al.
A P R I L 1 2 , 2 0 2 1 : 7 6 8 – 8 0 Landmark Analysis of RE-DUAL PCI
773
FIGURE 2 Landmark Analysis of Events Among Patients Who Received Drug-Eluting Stents
Events among patients who received drug-eluting stents during first 90 days after randomization and starting 90 days after randomization. The primary bleeding
endpoint is a composite of all International Society on Thrombosis and Hemostasis (ISTH) major bleeding events (MBE) or clinically relevant nonmajor bleeding events
(CRNMBE). *Cox proportional hazards model. For the dabigatran 110 mg versus warfarin comparison, the model was stratified by age, nonelderly versus elderly (<70
or $70 years in Japan and <80 or $80 years elsewhere). For the dabigatran 150 mg versus warfarin comparison, an unstratified model was used. †Wald confidence
limits. ‡Wald 2-sided p value from (stratified) Cox proportional hazards model. For the comparison with dabigatran 150 mg dual therapy, elderly patients outside the
United States are excluded. CI ¼ confidence interval; HR ¼ hazard ratio.
Peterson et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 4 , N O . 7 , 2 0 2 1
Landmark Analysis of RE-DUAL PCI A P R I L 1 2 , 2 0 2 1 : 7 6 8 – 8 0
7740.55 to 1.70; p ¼ 0.92; stent thrombosis: 6 [1.0%] vs. 4
[0.6%]; HR: 1.52; 95% CI: 0.43 to 5.38; p ¼ 0.52). There
were numerically higher rates of DTE with dabigatran
110 mg, but not 150 mg, versus warfarin
(Supplemental Table 4). During the first 90 days,
there was net clinical benefit among patients treated
with dabigatran 110 mg dual therapy (10.7% vs. 18.5%;
HR: 0.55; 95% CI: 0.42 to 0.72; p < 0.0001) and dabi-
gatran 150 mg dual therapy (12.2% vs. 18.2%; HR:
0.64; 95% CI: 0.48 to 0.86; p ¼ 0.0025) versus
warfarin triple therapy.
After 90 days, there was a persistent reduction in
ISTH major bleeding or CRNM bleeding in patients
who received dabigatran 110 mg dual therapy versus
warfarin dual therapy (9.8% vs. 13.9%; HR: 0.69;
95% CI: 0.50 to 0.93; p ¼ 0.0167). However, there was
a similar bleeding risk among patients who received
dabigatran 150 mg dual therapy versus warfarin dual
therapy (13.7% vs. 13.1%; HR: 1.01; 95% CI: 0.73 to1.41; p ¼ 0.94) (Figures 2 and 3). After 90 days, there
were similar rates of the secondary thrombotic end-
points among the 3 groups, with net clinical benefit
with dabigatran 110 mg dual therapy versus warfarin
dual therapy and similar net clinical benefit to dabi-
gatran 150 mg dual therapy versus warfarin dual
therapy (Supplemental Table 4, Supplemental
Figure 2).
EXPLORATORY ANALYSES: BMS. Among patients
who received BMS, there were similar reductions in
bleeding in the 2 dabigatran groups versus warfarin
prior to 30 days, as had been seen in the DES patients
prior to 90 days. After 30 days, there was a reduction
in ISTH major bleeding or CRNM bleeding with dabi-
gatran 110 mg versus warfarin and similar rates of
bleeding with dabigatran 150 mg versus warfarin (see
Supplemental Figure 3). There were insufficient
thrombotic events to make any comment about any of
FIGURE 3 Landmark Analysis of Patients Who Received Drug-Eluting Stents With Respect to the Primary Endpoint of ISTH Major Bleeding or CRNM Bleeding
(A) Events before and after the first 90 days after randomization in patients who received 110 dabigatran dual therapy versus warfarin triple therapy. (B) Events before
and after the first 90 days after randomization in patients who received 150 dabigatran dual therapy versus warfarin triple therapy. CRNM ¼ clinically relevant
nonmajor bleeding; ISTH ¼ International Society on Thrombosis and Hemostasis; other abbreviations as in Figure 1.
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776the secondary efficacy endpoints among patients who
received a BMS.DISCUSSION
Our study showed that in the early phase of treat-
ment, both doses of dabigatran plus a P2Y12 inhibitor
resulted in a substantial reduction in bleeding risk
compared with warfarin triple therapy. During the
first 30 days, there was a 55% reduction in bleeding
with dabigatran 110 mg dual therapy versus warfarin
triple therapy and a 54% reduction in bleeding with
dabigatran 150 mg dual therapy versus warfarin triple
therapy. There were also significant reductions in
recurrent bleeding events: 39% in dabigatran 110 mg
dual therapy and 23% in dabigatran 150 mg dual
therapy versus warfarin triple therapy.
After the removal of aspirin, dabigatran 110 mg
dual therapy continued to be associated with 31%
lower bleeding than warfarin dual therapy, while
dabigatran 150 mg dual therapy had a similar risk for
bleeding as warfarin dual therapy.
This analysis suggests that the differential risk for
bleeding between warfarin triple therapy and dabi-
gatran dual therapy seen in RE-DUAL PCI was related
to both the lack of aspirin and, for the 110 mg dose,
the lower level of anticoagulation; the large early re-
ductions in bleeding seem to be driven largely by lack
of aspirin in the dual-therapy arms (33–35). The post-
90-day landmark data suggest that there is an addi-
tional benefit to dabigatran 110 mg versus warfarin
with respect to bleeding, similar to the results of the
RE-LY (Randomized Evaluation of Long-Term Anti-
coagulation Therapy) study (36,37). This lower risk for
bleeding when stopping aspirin has now been well
established in the AUGUSTUS trial with 2  2 factorial
randomization (12). In AUGUSTUS, however, there
was an early increased risk for thrombotic events in
patients who were not treated with aspirin. In this
analysis, patients treated with dabigatran 150 mg dual
therapy had similar and large early reductions in
bleeding without an increase in thrombotic events.
FIRST 30 DAYS. During the first 30 days, neither of
the 2 dual-therapy groups had significantly higher
rates of DTE or unplanned revascularization. How-
ever, with great focus on these events, one could see
a numerically higher rate of DTE or unplanned
revascularization with dabigatran 110 mg versus
warfarin (2.9% vs. 2.0%; HR: 1.39; p ¼ 0.26), but not
with dabigatran 150 mg dual therapy versus warfarin
triple therapy (1.6% vs. 2.2%; HR: 0.70; p ¼ 0.34). The
number of stent thromboses and myocardial in-
farctions in DES patients tended to be greater duringthe first 90 days, but the number of events was so
small that it is difficult to draw any defini-
tive inferences.
Although a consistent benefit of the dual-therapy
approaches has been seen across the 5 trials
(including WOEST), the duration of aspirin post-PCI
and prior to randomization to dual therapy varied
across the different trials. In AUGUSTUS, the average
time to randomization (and the average duration of
aspirin therapy post-PCI in the patients who then
were randomized to dual therapy) was 6.6 days. On
the basis of these data, some clinicians have sug-
gested that patients be treated with aspirin for 1 week
following PCI (35). However, in RE-DUAL PCI, the
average time from PCI to randomization was only
1.6 days; thus, the effects of a dual-therapy approach,
without increased risk for thrombotic events, can
apply even with just 1 or 2 days of aspirin post-PCI.
From this analysis, it seems that the increased
bleeding risk of triple therapy is most pronounced
early, especially during the first 30 and 90 days.
Although recent practice may be to use a brief period
of triple therapy during the first months after PCI, this
may in fact be the time period with the highest risk
for bleeding with respect to the use of triple therapy,
except in select individualized cases. Given the lack
of a numeric increase in thrombotic events in the
early period for the dabigatran 150 mg dual-therapy
regimen, with significant net benefit, this may be an
appealing strategy for the early period post-PCI. As
discussed in recent European and U.S. consensus
statements, any use of aspirin beyond hospital
discharge should be individualized and limited to
those with the highest thrombotic risk and lowest
bleeding risk (38–40).
The first 30 days post-PCI are the most critical, not
only for the risk for thrombotic events but also
bleeding. It is interesting to note that the bleeding
curves and net clinical benefit curves begin to sepa-
rate at about 5 days after randomization with dabi-
gatran 150 mg dual therapy versus warfarin triple
therapy, corresponding perhaps with the residual
hemorrhagic effects of aspirin. Thus, in the first
30 days, removal of aspirin and treatment with
dabigatran 150 mg plus a P2Y12 inhibitor is safer and at
least as effective as warfarin triple therapy, with net
clinical benefit. In contrast, in a recent landmark
analysis of AUGUSTUS, there were more severe
thrombotic events during the first 30 days among
patients treated with oral anticoagulation plus a P2Y12
inhibitor without aspirin (22). This is a plausible
benefit of the 150-mg dose, as dabigatran 150 mg
previously has been shown to be more effective than
warfarin at preventing ischemic stroke in RE-LY and
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777is the only DOAC regimen shown to have that benefit
over warfarin (37,41,42). As such, this 150-mg dosing
regimen of dabigatran may be ideal for many pa-
tients, especially those challenging patients with both
elevated bleeding and thrombotic risk.
AFTER 30 DAYS. After 30 days, however, there was
net clinical benefit with dabigatran 110 mg dual
therapy versus warfarin and similar outcomes for
both bleeding and thrombotic events (and the net
clinical benefit endpoint) for dabigatran 150 mg dual
therapy versus warfarin. As a result of this landmark
analysis data, for a patient at high bleeding risk, one
might consider using dabigatran 150 mg dual therapy
for the first 30 days after PCI and then continuing
with that dose or reducing the dose to 110 mg (if
available), as a way to optimize bleeding and throm-
botic risk.
Although the increase of bleeding associated with
adding aspirin to warfarin has long been established,
aspirin use has repeatedly been shown to increase the
risk for bleeding when added to DOACs as well
(10,12,18). After the discontinuation of aspirin, the
reduced bleeding profile of the dabigatran 110 mg
group over the warfarin group, as well as the similar
bleeding profile of the dabigatran 150 group and
warfarin, again parallels the results of the RE-LY trial,
in which dabigatran 110 mg twice daily showed a su-
perior bleeding profile over warfarin, while dabiga-
tran 150 mg twice daily showed no difference in
bleeding compared with warfarin (37). Unlike the
other DOACs, however, dabigatran does not have
specific dose reduction criteria in the United States,
and a 110-mg twice-daily dose is not yet approved in
the United States for atrial fibrillation, though it is
approved for venous thromboembolism (in Europe,
the 110-mg dose has been approved for atrial fibril-
lation as well) (41–43).
90-DAY LANDMARK. The 90-day landmark analysis,
limited to patients who received DES, provides some
important insight into the large early reductions in
bleeding in both arms of dabigatran dual therapy
versus warfarin because patients in the warfarin arms
who received DES discontinued aspirin after 90 days.
Thus, in the case of dabigatran 150 mg, the early net
clinical benefit and large bleeding reduction seems to
be related to the lack of aspirin alone. In contrast, in
the case of dabigatran 110 mg, net clinical benefit and
reductions in bleeding persist beyond 90 days, sug-
gesting an additional benefit to lower dose anti-
coagulation, beyond the omission of early
aspirin therapy.STUDY LIMITATIONS. Limitations of this study
include multiple comparisons that exist with any
secondary analysis of a clinical trial. The RE-DUAL
PCI study was not powered for this landmark anal-
ysis, nor was this a pre-specified analysis. Thus, all p
values should be regarded as exploratory. Landmark
analyses have inherent limitations, including the
introduction of survival bias, the arbitrariness of a
landmark cutoff, and the erosion of randomization for
the post-cutoff period. The higher pre-landmark risk
for bleeding in the warfarin groups likely skews the
post-landmark results in favor of the warfarin therapy
group, because surviving patients who were free from
the primary bleeding endpoint at the landmark cutoff
were included, leading to the selection of those who
did not bleed. We did not investigate relative
bleeding rates among patients who were treated
with clopidogrel versus ticagrelor, but in a recent
analysis, Oldgren et al. (44) showed that there was a
consistent benefit with dabigatran dual versus
warfarin triple therapy in patients who were treated
with clopidogrel or with ticagrelor in RE-DUAL PCI.
Other limitations of this study are shared with the
RE-DUAL PCI study, such as the lack of a comparison
arm with warfarin and no aspirin (24). The effect of
aspirin in combination with dabigatran was not
studied in RE-DUAL PCI; only the AUGUSTUS trial was
able to compare warfarin versus DOAC dual therapy
prospectively. In addition, RE-DUAL PCI was not
powered to detect differences in thrombotic events;
the same is true for each of the trials studying DOACs
in patients with atrial fibrillation who undergo PCI
(45). Yet it is encouraging that the number of
thrombotic events is this small, even if any inferences
we may draw from between-group comparisons
are limited.
CONCLUSIONS
Both doses of dabigatran plus a P2Y12 inhibitor
markedly reduced the risk for early bleeding
compared with warfarin triple therapy. There was
early net clinical benefit with both doses of dabiga-
tran dual therapy versus warfarin triple therapy,
without a numeric increase in thrombotic events in
patients treated with dabigatran 150 mg dual therapy.
After 30 days and after aspirin was discontinued,
110 mg dabigatran dual therapy continued to have a
lower bleeding risk than warfarin dual therapy, and
150 mg dabigatran dual therapy had a similar bleeding
risk profile to warfarin dual therapy. On the basis of
this exploratory analysis, either combination could be
PERSPECTIVES
WHAT IS KNOWN? Patients with atrial fibrillation
who undergo PCI are at significantly increased risk for
both bleeding and thrombotic events.
WHAT IS NEW? In a landmark analysis of the RE-
DUAL PCI trial, there were large reductions in the
primary bleeding endpoint before 30 days, without a
significant increase in thrombotic events in patients
treated with dabigatran dual therapy versus warfarin
triple therapy.
WHAT IS NEXT? Further investigation of the toler-
ability and efficacy of dual-antithrombotic therapy
among patients at particularly increased risk for
ischemic events or with recurrent ischemic events is
warranted.
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778a safe substitution for warfarin when combined with a
P2Y12 inhibitor, without the need for aspirin at any
point after the doses received peri-PCI, except in
select cases (40). At the same time, our analysis
suggests the benefits observed can be achieved with a
briefer period of aspirin therapy immediately post-
PCI (1 to 2 days) than was used in AUGUSTUS (6 to
7 days). In addition, given the net clinical benefit,
dabigatran 150 mg may be considered to allow
reduced bleeding and no numeric increase in throm-
botic events, especially among the subset of patients
who have elevated risk for both bleeding and
thrombotic events.
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